Abbott Laboratories $ABT Shares Sold by Fort Washington Investment Advisors Inc. OH

Key Points

• Fort Washington Investment Advisors Inc. OH reduced its stake in Abbott Laboratories by 15.5%, now owning 26,810 shares worth approximately $3.6 million.
• Numerous hedge funds have adjusted their holdings in Abbott, with Brighton Jones LLC increasing its stake by 10.1% in the last quarter, reaching a total of 51,719 shares valued at $5.85 million.
• Abbott Laboratories has reported a quarterly earnings of $1.26 EPS, meeting consensus estimates, with revenue up 7.4% year-over-year, and has set its FY 2025 guidance between $5.100-5.200 EPS.

Fort Washington Investment Advisors Inc. OH decreased its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 15.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,810 shares of the healthcare product maker's stock after selling 4,901 shares during the period. Fort Washington Investment Advisors Inc. OH's holdings in Abbott Laboratories were worth $3,646,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ABT. Brighton Jones LLC increased its holdings in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its stake in shares of Abbott Laboratories by 28.8% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 42,105 shares of the healthcare product maker's stock worth $5,585,000 after buying an additional 9,412 shares during the last quarter. Allied Investment Advisors LLC grew its stake in Abbott Laboratories by 4.0% in the 1st quarter. Allied Investment Advisors LLC now owns 90,070 shares of the healthcare product maker's stock valued at $11,948,000 after acquiring an additional 3,489 shares during the last quarter. Abner Herrman & Brock LLC purchased a new position in Abbott Laboratories during the 1st quarter valued at about $18,225,000. Finally, Aletheian Wealth Advisors LLC acquired a new position in Abbott Laboratories during the first quarter worth about $210,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and raised their price target for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Wells Fargo & Company decreased their price objective on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a report on Friday, July 18th. Leerink Partners initiated coverage on Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price for the company. William Blair raised Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Finally, Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research note on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $145.22.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $133.62 on Monday. The company has a market cap of $232.56 billion, a P/E ratio of 16.74, a PEG ratio of 2.53 and a beta of 0.69. The business has a 50 day moving average of $131.14 and a two-hundred day moving average of $131.16. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business's revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.